AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02280291
Drug: Ankle SSB
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
Trial: NCT02280291
Drug: Ankle OnQ
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
Trial: NCT03165136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of hydroxychloroquine
Trial: NCT00065741
Drug: silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01636024
Drug: AZD7594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension inhaled via Spira nebuliser
Trial: NCT01636024
Drug: Placebo to match
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo inhaled via Spira nebuliser
Trial: NCT00385268
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT01157416
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
Trial: NCT04156750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT01975779
Drug: Cohort A2: Lu AE58054 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
Trial: NCT01975779
Drug: Cohort B1: Lu AE58054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two single oral doses 60 mg with \>=7 days washout.
Trial: NCT01005719
Drug: Prevacid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
Trial: NCT01368341
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet, 100 mg, b.i.d. 14 days
Trial: NCT00412698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
Trial: NCT04405505
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT02918487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive compound that is similar looking as the intervention
Trial: NCT01669369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
Trial: NCT01350037
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
Trial: NCT01617434
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
Trial: NCT03682094
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
Trial: NCT02930655
Drug: Enzyme replacement therapy (ERT)
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
Trial: NCT00659919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02998437
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
Trial: NCT02662660
Drug: Metamizole and Acetaminophen iv
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
Trial: NCT02213289
Drug: ABT-806
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-806
Trial: NCT00307060
Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02213289
Drug: Standard cytotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
Trial: NCT03417180
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
Trial: NCT00248313
Drug: Rapamune®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02932475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered to match active drug
Trial: NCT01448291
Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
Trial: NCT01323257
Drug: erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
Trial: NCT01323257
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 7 days (Trt A, C, D)
Trial: NCT01323257
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsule once daily for 7 days (Trt F)
Trial: NCT01323257
Drug: erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg tablets three times a day for 7 days (Trt C)
Trial: NCT03462446
Drug: Vitamin K antagonists (VKAs)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
Trial: NCT02476981
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
Trial: NCT01689207
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART A, PART B, PART C: matching placebo IV infusions
Trial: NCT00364845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefilled syringe placebo, to match active arm
Trial: NCT03705962
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02624401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of saline (Ringer's Acetate)
Trial: NCT02614872
Drug: GLASSIA® and Institution standard of care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
Trial: NCT00649467
Drug: Topamax® Sprinkle Capsules 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg, single dose applesauce
Trial: NCT03765801
Drug: GRTA9906 60 mg PR tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRTA9906 60 mg PR tablet
Trial: NCT03765801
Drug: GRTA9906 60 mg IR capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRTA9906 60 mg IR capsule
Trial: NCT03141086
Drug: LML134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LML134
Trial: NCT03141086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00088634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to 40mg lurasidone tablets
Trial: NCT02150824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 high dose matching placebo once daily
Trial: NCT02150824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 medium dose matching placebo once daily
Trial: NCT02150824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 high dose matching placebo once daily add on to background metformin
Trial: NCT00524316
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transarterial chemoembolization
Trial: NCT02884817
Drug: Experimental: essential oils and ELA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
Trial: NCT02619019
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
Trial: NCT04035135
Drug: ANX005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug
Trial: NCT00147004
Drug: hydrocortisone sodium succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
Trial: NCT00147004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00013624
Drug: IV Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01803763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
Trial: NCT02929563
Drug: Placebo (for pantoprazole)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03638726
Drug: Atropine sulfate and epinephrine
RxNorm normalized name: atropine / epinephrine / tyramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
Trial: NCT04552535
Drug: Second line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT00540436
Drug: GSK1325760A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
Trial: NCT04640324
Drug: Nutraceutical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
Trial: NCT03531437
Drug: 15 µg ethinylestradiol and 60 µg gestodene
RxNorm normalized name: gestodene and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04019093
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
Trial: NCT03558061
Drug: ALK4290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALK4290 400 mg tablet twice a day
Trial: NCT03962283
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Rifaximin four times daily
Trial: NCT01300611
Drug: TXA127 300 mcg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, 300 mcg/kg/day for 28 days
Trial: NCT01300611
Drug: TXA127 1000 mcg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, 1000 mcg/kg/day for 28 days
Trial: NCT01574313
Drug: 0.25mg, fludiazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg of erispan@ (fludiazine), p.o. one dose only.
Trial: NCT01574313
Drug: 25mg cephadol@ (diphenidol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg cephadol@ (diphenidol) p.o. one dose only.
Trial: NCT01574313
Drug: 200mg kentons@ (tocopherol nicotinate).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
Trial: NCT02306187
Drug: Edirol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
Trial: NCT02531035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, before the first meal of the day
Trial: NCT00119301
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00119301
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02380352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
Trial: NCT02772965
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits.
Trial: NCT04275986
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks
Trial: NCT02410902
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Trial: NCT04928079
Drug: Anti-Parkinsonian Drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using anti-parkinsonian drugs if needed
Trial: NCT02322892
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
Trial: NCT01043185
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg orally in the morning and 90 mg in the evening for 1 day
Trial: NCT01043185
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg orally in the morning and 120 mg in the evening for 1 day
Trial: NCT01043185
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg orally in the morning and 240 mg in the evening for 1 day
Trial: NCT01043185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
Trial: NCT01838174
Drug: IV methylprednisolone (steroids)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 days of intravenous methylprednisolone followed by 11 days of oral taper
Trial: NCT00137436
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
Trial: NCT00701727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, once a day, for 7 weeks
Trial: NCT02757066
Drug: NPC-15 Granules Higher Dose
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin granule which contains 4 mg melatonin
Trial: NCT00210080
Drug: Uridine 5'-Triphosphate (UTP) Solution for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01383395
Drug: simvastatin/cilostazol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02856581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01290172
Drug: Administration of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy.
Trial: NCT02218658
Drug: WE941 OD tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04389840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline
Trial: NCT01562561
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
Trial: NCT00153738
Drug: phytosterol
RxNorm normalized name: Phytosterol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04649203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Trial: NCT03478319
Drug: ACE-2494 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombination fusion protein
Trial: NCT00502307
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solid oral capsule containing excipients dosed daily for three weeks per month